Original articleSubfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Section snippets
Methods
The clinical examinations for diagnosis of PCV included indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens or noncontact lens, digital fluorescein angiography, and indocyanine green angiography (ICGA). We used a digital imaging system with an infrared camera and standard fundus camera (TRC-50 IX/IMAGEnet H1024 system; Topcon, Tokyo, Japan) and a confocal laser scanning system (HRA-2; Heidelberg Engineering, Dossenheim, Germany). The best-corrected visual acuity (BCVA) was
Results
Twenty-seven eyes of 27 consecutive patients with newly diagnosed PCV were included. Sixteen eyes of 16 patients (12 men, 4 women; mean age, 71.8 years) comprised the PDT group. Eleven eyes of 11 patients (6 men, 5 women; mean age, 71.0 years) comprised the ranibizumab plus PDT group. The lesion area included the fovea in all cases. The mean GLD for PDT was 3013 ± 1059 μm in the PDT group and 2905 ± 1122 μm in the ranibizumab plus PDT group. ICGA showed that the polypoidal lesions in all cases
Discussion
In the current study, PDT occluded the polypoidal lesions and decreased the retinal and choroidal thicknesses in eyes with PCV. The combination therapy of ranibizumab and PDT reduced the exudation just after PDT and maintained the retinal thinning until 6 months after treatment. Consequently, the BCVA after combination therapy was relatively better than that after PDT monotherapy.
PCV is more common in Asia than in white persons39, 40 and is thought to account for approximately half of patients
Ichiro Maruko, MD, was born and raised in Japan. He is a graduate of the Fukushima Medical University School of Medicine, Fukushima, Japan in 1999. He worked at College of Optometry, University of Houston, Houston, Texas, USA from 2002 to 2004. He received MD and PhD at Fukushima Medical University School of Medicine. His major interest includes retinal and choroidal imaging.
Dr Maruko is currently a Research Associate of the Department of Ophthalmology, Fukushima Medical University School of
References (47)
Guidelines for PDT in Japan
Ophthalmology
(2008)- et al.
Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin
Am J Ophthalmol
(2002) - et al.
Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series
Ophthalmology
(2004) - et al.
Vascular targeting in photodynamic occlusion of subretinal vessels
Ophthalmology
(1994) - et al.
Liposomal benzoporphyrin derivative verteporfin photodynamic therapySelective treatment of choroidal neovascularization in monkeys
Ophthalmology
(1996) - et al.
Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization
Am J Ophthalmol
(2002) - et al.
Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization
Am J Ophthalmol
(2006) - et al.
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration
Ophthalmology
(2007) - et al.
Enhanced depth imaging spectral-domain optical coherence tomography
Am J Ophthalmol
(2008) Economic implications of current age-related macular degeneration treatments
Ophthalmology
(2009)
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
Clin Ther
Subfoveal choroidal thickness after treatment of central serous chorioretinopathy
Ophthalmology
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP Report 1
Arch Ophthalmol
Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Am J Ophthalmol
Verteporfin Roundtable 2000 and 2001 Participants; Study Group Principal InvestigatorsGuidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes
Retina
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update
Retina
Treatment of polypoidal choroidal vasculopathy with photodynamic therapy
Retina
Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy
Am J Ophthalmol
Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy
Retina
Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment
Br J Ophthalmol
Histopathological changes following photodynamic therapy in human eyes
Arch Ophthalmol
Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes
Graefes Arch Clin Exp Ophthalmol
Photodynamic effects on choroidal neovascularization and physiological choroid
Invest Ophthalmol Vis Sci
Cited by (142)
Cytotoxicity of structurally-modified chlorins aimed for photodynamic therapy applications
2022, Journal of Photochemistry and Photobiology A: ChemistryMultimodal Imaging Comparison of Polypoidal Choroidal Vasculopathy Between Asian and Caucasian Populations
2022, American Journal of OphthalmologyAntileishmanial activity of amphiphilic chlorin derivatives mediated by photodynamic therapy
2020, Photodiagnosis and Photodynamic TherapyIntravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes
2024, Graefe's Archive for Clinical and Experimental Ophthalmology
Ichiro Maruko, MD, was born and raised in Japan. He is a graduate of the Fukushima Medical University School of Medicine, Fukushima, Japan in 1999. He worked at College of Optometry, University of Houston, Houston, Texas, USA from 2002 to 2004. He received MD and PhD at Fukushima Medical University School of Medicine. His major interest includes retinal and choroidal imaging.
Dr Maruko is currently a Research Associate of the Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan.